Brief: Adagene Inc - Cash And Cash Equivalents Were US$208.3 Mln As Of June 30, 2021, Compared To US$75.2 Mln As Of Dec. 31, 2020
26/08/2021 12:49
Aug 26 (Reuters) - Adagene Inc 978y.F :
* ADAGENE REPORTS FINANCIAL RESULTS FOR THE SIX MONTHS ENDED
JUNE
30, 2021 AND PROVIDES CORPORATE UPDATES
* ADAGENE INC - CASH AND CASH EQUIVALENTS WERE US$208.3
MILLION AS
OF JUNE 30, 2021, COMPARED TO US$75.2 MILLION AS OF DECEMBER 31,
2020
Source text for Eikon: ID:nGNXb61HZg
Further company coverage: 978y.F
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate